Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease

Martin Farlow, Jeffrey L. Cummings, Jason T. Olin, Meng Xiangyi Meng

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rivastigmine has beneficial effects on cognitive functioning in Alzheimer's disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scaleg-cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≥ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P <.001) and praxis (P <.001); greatest treatment responses were seen on memory items (P <.0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.

Original languageEnglish
Pages (from-to)347-352
Number of pages6
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Volume25
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Rivastigmine
Alzheimer Disease
Placebos
Cholinesterase Inhibitors
Capsules
Language

Keywords

  • Alzheimer's disease
  • Cognition
  • Language
  • Memory
  • Praxis
  • Rivastigmine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology
  • Medicine(all)

Cite this

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. / Farlow, Martin; Cummings, Jeffrey L.; Olin, Jason T.; Xiangyi Meng, Meng.

In: American Journal of Alzheimer's Disease and other Dementias, Vol. 25, No. 4, 2010, p. 347-352.

Research output: Contribution to journalArticle

Farlow, Martin ; Cummings, Jeffrey L. ; Olin, Jason T. ; Xiangyi Meng, Meng. / Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. In: American Journal of Alzheimer's Disease and other Dementias. 2010 ; Vol. 25, No. 4. pp. 347-352.
@article{70bb6054f7884b11bf01e75e7ea7a7d3,
title = "Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease",
abstract = "Rivastigmine has beneficial effects on cognitive functioning in Alzheimer's disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scaleg-cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≥ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P <.001) and praxis (P <.001); greatest treatment responses were seen on memory items (P <.0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.",
keywords = "Alzheimer's disease, Cognition, Language, Memory, Praxis, Rivastigmine",
author = "Martin Farlow and Cummings, {Jeffrey L.} and Olin, {Jason T.} and {Xiangyi Meng}, Meng",
year = "2010",
doi = "10.1177/1533317510365344",
language = "English",
volume = "25",
pages = "347--352",
journal = "American Journal of Alzheimer's Disease and other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease

AU - Farlow, Martin

AU - Cummings, Jeffrey L.

AU - Olin, Jason T.

AU - Xiangyi Meng, Meng

PY - 2010

Y1 - 2010

N2 - Rivastigmine has beneficial effects on cognitive functioning in Alzheimer's disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scaleg-cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≥ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P <.001) and praxis (P <.001); greatest treatment responses were seen on memory items (P <.0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.

AB - Rivastigmine has beneficial effects on cognitive functioning in Alzheimer's disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scaleg-cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≥ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P <.001) and praxis (P <.001); greatest treatment responses were seen on memory items (P <.0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.

KW - Alzheimer's disease

KW - Cognition

KW - Language

KW - Memory

KW - Praxis

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=77953635746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953635746&partnerID=8YFLogxK

U2 - 10.1177/1533317510365344

DO - 10.1177/1533317510365344

M3 - Article

VL - 25

SP - 347

EP - 352

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

SN - 1533-3175

IS - 4

ER -